{"ATC Code":["R - Respiratory system","R06 - Antihistamines for systemic use","R06A - Antihistamines for systemic use","R06AX - Other antihistamines for systemic use","R06AX26 - Fexofenadine","QR - Respiratory system","QR06 - Antihistamines for systemic use","QR06A - Antihistamines for systemic use","QR06AX - Other antihistamines for systemic use","QR06AX26 - Fexofenadine"],"Abbreviation":[],"Absorption, Distribution and Excretion":"Fexofenadine is rapidly absorbed following oral administration and its absolute bioavailability is approximately 33%. The Tmax following oral administration is approximately 1-3 hours. The steady-state AUCss(0-12h) and Cmax following twice daily dosing of 60mg are 1367 ng/mL.h and 299 ng/mL, respectively.  Fexofenadine AUC is decreased by \u003e20% when coadministered with fruit juices (e.g. apple, orange, grapefruit) due to their inhibition of OATP transporters - for this reason, prescribing information recommends administering fexofenadine only with water. Similarly, coadministration of fexofenadine with a high-fat meal appears to decrease AUC and Cmax by \u003e20%.","Adverse Effects":"The most common dose-dependent adverse drug reactions associated with fexofenadine include drowsiness, fatigue, and dry mouth. In addition, post-marketing surveillance has reported rare occurrences of Stevens-Johnson syndrome or toxic epidermal necrolysis induced by fexofenadine.","Aliases":["Fexofenadine","83799-24-0","Carboxyterfenadine","Terfenadine carboxylate","Terfenadine-COOH","Terfenadine acid metabolite","Telfast","MDL 16455","Fexofenadina","2-(4-{1-Hydroxy-4-[4-(hydroxydiphenylmethyl)piperidin-1-yl]butyl}phenyl)-2-methylpropanoic acid","2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid","4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)-1-piperidinyl)butyl)-α,α-dimethylbenzeneacetic acid","E6582LOH6V","MDL-16455","CHEBI:5050","Dtxsid00861411","2-[4-(1-hydroxy-4-{4-[hydroxy(diphenyl)methyl]piperidin-1-yl}butyl)phenyl]-2-methylpropanoic acid","Benzeneacetic acid, 4-(1-hydroxy-4-(4-(hydroxydiphenylmethyl)-1-piperidinyl)butyl)-α,α-dimethyl-","4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethylbenzeneacetic acid","fexofenadinum","2-(4-(1-hydroxy-4-(4-(hydroxy(diphenyl)methyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid","Benzeneacetic acid, 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethyl-","Dtxcid50197277","R06AX26","α-(4-(1-carboxy-1-methylethyl)phenyl)-4-hydroxydiphenylmethyl-1-piperidinebutanol","2-(4-(1-hydroxy-4-(4-(hydroxy(diphenyl)methyl)piperidin-1-ium-1-yl)butyl)phenyl)-2-methylpropanoate","801-893-7","Allegra","Mfcd00871892","CHEMBL914","Benzeneacetic acid,4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-a,a-dimethyl-","MDL-16455; Terfenadine carboxylate","Fexofendine","2-[4-[1-hydroxy-4-[4-[hydroxy(diphenyl)methyl]-1-piperidyl]butyl]phenyl]-2-methyl-propanoic acid","HSDB 7486","Ncgc00015453-05","Unii-e6582loh6v","Sr-01000075889","Terfenidine carboxylate, MDL 16455","Spectrum_001914","Fexofenidine hydrochloride","2-(4-[1-Hydroxy-4-[4-(hydroxy-diphenyl-methyl)-piperidin-1-yl]-butyl]-phenyl)-2-methyl-propionic acid","Spectrum2_001179","Spectrum3_001921","Spectrum4_000204","Spectrum5_001474","MDL-16455 free base","Ec 801-893-7","F 9427","Schembl4900","Lopac0_000488","BSPBio_003521","KBioGR_000807","KBioSS_002456","SPBio_001197","GTPL4819","orb1306379","BDBM22874","KBio2_002449","KBio2_005017","KBio2_007585","KBio3_002742","GLXC-07959","HMS3261B17","HMS3370C16","HY-B0801","Tox21_500488","BBL029080","EBC-27245","STK624102","Akos005557315","CCG-204579","DB00950","FF23281","LP00488","Sdccgsbi-0050472.p003","Ncgc00015453-03","Ncgc00015453-04","Ncgc00015453-06","Ncgc00015453-10","Ncgc00015453-19","Ncgc00092389-02","Ncgc00092389-03","Ncgc00092389-04","Ncgc00261173-01","4-(1-Hydroxy-4-(4-(hydroxydiphenyl-methyl)-1- piperidinyl)butyl)-α-dimethylbenzeneacetic acid","2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)-piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid","AC-37658","AS-35188","Sbi-0050472.p002","DB-016658","DB-226998","CS-0012429","EU-0100488","NS00010515","En300-58439","C06999","D07958","Ab00876239_06","Ab00876239_07","439F408","799F240","L000869","Q415122","Sr-01000075889-1","Brd-a73368467-003-02-8","Brd-a73368467-003-07-7","Brd-a73368467-003-16-8","Brd-a73368467-003-17-6","Brd-a73368467-003-18-4","4-[4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]-1-hydroxybutyl]-α,α-dimethylbenzeneacetic-acid","1319714-86-7","2-[4-(1-Hydroxy-4-{4-[hydroxy(diphenyl)methyl]-1-piperidinyl}butyl)phenyl]-2-methylpropanoic acid","2-[4-(1-Hydroxy-4-{4-[hydroxydi(phenyl)methyl]piperidin-1-yl}butyl)phenyl]-2-methylpropanoic acid","2-[4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidyl]butyl]phenyl]-2-methyl-propanoic acid","4-[1-Hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethyl-benzene-acetic Acid","4-[4-(4-(Hydroxydiphenylmethyl)-1-piperidinyl]-1-hydroxybutyl]-α, α-dimethylbenzeneacetic acid","4-[4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]-1-hydroxybutyl] -α,α-dimethylbenzeneacetic acid","4-[4-[4-(Hydroxydiphenylmethyl)-1-piperidinyl]-1-hydroxybutyl]-α,α-dimethylbenzeneacetic acid","4-[4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]-1-hydroxybutyl]-α,α-dimethylphenylacetic acid","4-[4[4-(hydroxydiphenylmethyl)-1-piperidinyl]-1-hydroxybutyl]-α,α-dimethylbenzeneacetic acid","racemic 4-[4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]-1-hydroxybutyl]-α,α-dimethylbenzeneacetic acid"],"Biological Half-Life":"The terminal elimination half-life is approximately 11-15 hours.","CAS":"83799-24-0","Chemical Classes":"Pharmaceutical","ChemicalClasses":["carboxylic acid"],"Chirality":"racemic","Color/Form":"Crystals from methanol-butanone","Drug Classes":["Breast Feeding","Lactation","Milk, Human","Antihistamines","Nonsedating Antihistamines"],"Drug Indication":"In the United States, fexofenadine is indicated for the symptomatic treatment of allergic rhinitis in patients ≥2 years old and chronic idiopathic urticaria in patients ≥6 months old. In Canada, fexofenadine carries the same indications but is approved only for patients ≥12 years old. Fexofenadine is also available in combination with [pseudoephedrine] for the symptomatic treatment of season allergic rhinitis in patients ≥12 years old.","Drug Warnings":"In controlled clinical studies in patients 12 years of age and older with allergic rhinitis receiving oral fexofenadine hydrochloride dosages of 60 mg twice daily or placebo, drowsiness or fatigue occurred in 1.3% of patients, compared with 0.9% of those receiving placebo. In these studies in patients receiving fexofenadine hydrochloride dosages of 180 mg once daily (as conventional tablets) or placebo, headache was reported in 10.6 or 7.5% of patients, respectively. In controlled studies in children 6-11 years of age with seasonal allergic rhinitis receiving fexofenadine hydrochloride dosages of 30 mg twice daily or placebo, headache was reported in 7.2 or 6.6% of patients, respectively, while pain was reported in 2.4 or 0.4% of patients, respectively.","DurationOfAction":"","EliminationHalfLife":"14.4 hours","Esters":[],"European Community (EC) Number":"801-893-7","FDA Pharmacological Classification":[{"Name":"FDA UNII","ReferenceNumber":22,"Value":{"StringWithMarkup":[{"String":"E6582LOH6V"}]}},{"Name":"Active Moiety","ReferenceNumber":22,"Value":{"StringWithMarkup":[{"String":"FEXOFENADINE"}]}},{"Name":"Pharmacological Classes","ReferenceNumber":22,"Value":{"StringWithMarkup":[{"Markup":[{"Extra":"CID-774","Length":9,"Start":29,"Type":"PubChem Internal Link","URL":"https://pubchem.ncbi.nlm.nih.gov/compound/Histamine"}],"String":"Mechanisms of Action [MoA] - Histamine H1 Receptor Antagonists"}]}},{"Name":"Pharmacological Classes","ReferenceNumber":22,"Value":{"StringWithMarkup":[{"Markup":[{"Extra":"CID-774","Length":9,"Start":40,"Type":"PubChem Internal Link","URL":"https://pubchem.ncbi.nlm.nih.gov/compound/Histamine"}],"String":"Established Pharmacologic Class [EPC] - Histamine-1 Receptor Antagonist"}]}},{"Name":"FDA Pharmacology Summary","ReferenceNumber":22,"Value":{"StringWithMarkup":[{"Markup":[{"Extra":"CID-3348","Length":12,"Start":0,"Type":"PubChem Internal Link","URL":"https://pubchem.ncbi.nlm.nih.gov/compound/Fexofenadine"},{"Extra":"CID-774","Length":9,"Start":18,"Type":"PubChem Internal Link","URL":"https://pubchem.ncbi.nlm.nih.gov/compound/Histamine"},{"Extra":"CID-3348","Length":12,"Start":78,"Type":"PubChem Internal Link","URL":"https://pubchem.ncbi.nlm.nih.gov/compound/fexofenadine"},{"Extra":"CID-774","Length":9,"Start":99,"Type":"PubChem Internal Link","URL":"https://pubchem.ncbi.nlm.nih.gov/compound/Histamine"}],"String":"Fexofenadine is a Histamine-1 Receptor Antagonist. The mechanism of action of fexofenadine is as a Histamine H1 Receptor Antagonist."}]}}],"Formating":[],"HMDB ID":"HMDB0005030","HeavyAtomCount":37,"Human Drugs":"Breast Feeding; Lactation; Milk, Human; Antihistamines; Nonsedating Antihistamines","IUPACName":"2-[4-[1-hydroxy-4-[4-[hydroxy(diphenyl)methyl]piperidin-1-yl]butyl]phenyl]-2-methylpropanoic acid","InChI":"InChI=1S/C32H39NO4/c1-31(2,30(35)36)25-17-15-24(16-18-25)29(34)14-9-21-33-22-19-28(20-23-33)32(37,26-10-5-3-6-11-26)27-12-7-4-8-13-27/h3-8,10-13,15-18,28-29,34,37H,9,14,19-23H2,1-2H3,(H,35,36)","InChIKey":"RWTNPBWLLIMQHL-UHFFFAOYSA-N","Interactions":"Increased concentrations of fexofenadine have been reported in 2 controlled drug interaction studies in healthy individuals receiving 120 mg of fexofenadine hydrochloride twice daily concomitantly with erythromycin dosages of 500 mg every 8 hours or ketoconazole 400 mg once daily.  In these studies, area under the plasma-concentration time curve (AUC) of fexofenadine increased by 109 or 164% following concomitant administration with erythromycin or ketoconazole, respectively, while peak plasma concentrations of fexofenadine increased by 82 or 135%, respectively.  However, no clinically important adverse effects or changes in the QT interval corrected for rate (QTc) were reported after concomitant administration of erythromycin or ketoconazole with fexofenadine.","MeSH Headers":[{"Id":"M0198490","Link":"https://id.nlm.nih.gov/mesh/M0198490.html","Name":"4-(1-hydroxy-4-(4-(hydroxydiphenylmethyl)-1-piperidinyl)butyl)-alpha,alpha-dimethylbenzeneacetic acid","Ref":84},{"Id":"M0245918","Link":"https://id.nlm.nih.gov/mesh/M0245918.html","Name":"fexofenadine","Ref":85},{"Id":"DescTree","Link":"https://www.nlm.nih.gov/mesh/meshhome.html","Name":"MeSH Tree","Ref":87},{"Id":"PubMed from MeSH","Link":"https://www.nlm.nih.gov/mesh/meshhome.html","Name":null,"Ref":112},{"Id":"M0028295","Link":"https://id.nlm.nih.gov/mesh/M0028295.html","Name":"Anti-Allergic Agents","Ref":113},{"Id":"M0419330","Link":"https://id.nlm.nih.gov/mesh/M0419330.html","Name":"Histamine H1 Antagonists, Non-Sedating","Ref":114}],"MeSH Pharmacological Classification":[{"Id":"M0028295","Link":"https://id.nlm.nih.gov/mesh/M0028295.html","Name":"Anti-Allergic Agent","Ref":113},{"Id":"M0419330","Link":"https://id.nlm.nih.gov/mesh/M0419330.html","Name":"Histamine H1 Antagonists, Non-Sedating","Ref":114}],"Mechanism of Action":"The H\u003csub\u003e1\u003c/sub\u003e histamine receptor is responsible for mediating hypersensitivity and allergic reactions. Exposure to an allergen results in degranulation of mast cells and basophils, which then release histamine and other inflammatory mediators. Histamine binds to, and activates, H\u003csub\u003e1\u003c/sub\u003e receptors, which results in the further release of pro-inflammatory cytokines, such as interleukins, from basophils and mast cells. These downstream effects of histamine binding are responsible for a wide variety of allergic symptoms, such as pruritus, rhinorrhea, and watery eyes.  Fexofenadine is considered an “inverse agonist” of the H\u003csub\u003e1\u003c/sub\u003e receptor because it binds to and stabilizes the inactive form of the receptor, preventing its activation and subsequent downstream effects. It has a potent and selective affinity for H\u003csub\u003e1\u003c/sub\u003e receptors, and there is no evidence that it carries antidopaminergic, antiserotonergic, anticholinergic, sedative, or adrenergic blocking activity. Fexofenadine does not cross the blood-brain barrier and thus is unlikely to cause significant CNS effects.","Melting Point":"195-197 °C","Metabolism/Metabolites":"Fexofenadine is very minimally metabolized, with only 5% of an ingested dose undergoing hepatic metabolism. The only identified metabolites are a methyl ester of fexofenadine (3.6% of the total dose) and MDL 4829 (1.5% of the total dose). The enzymes responsible for this metabolism have not been elucidated.","MolecularFormula":"C\u003csub\u003e32\u003c/sub\u003eH\u003csub\u003e39\u003c/sub\u003eNO\u003csub\u003e4\u003c/sub\u003e","MolecularWeight":"501.7 g/mol","Opticalactivity":"( + / - )","Pharmacodynamics":"Fexofenadine relieves allergy symptoms by antagonizing the actions of histamine, an endogenous compound predominantly responsible for allergic symptomatology. The relatively long duration of action of fexofenadine (approximately 24 hours) allows for once or twice daily dosing, and its rapid absorption allows for an onset of action within 1-3 hours. Fexofenadine should not be taken with fruit juice, as this may impair its absorption.","Physical Description":"Solid","PubChemId":3348,"Record Description":["LiverTox|Respiratory|Allergy symptoms|Antihistamine"],"Records":{"UNII":{"Impurities":[]}},"RefChem":"5830","RefCount":6,"RefCur":"","References":[{"Name":"Wikipedia","Urls":[{"Link":"https://en.wikipedia.org/wiki/Fexofenadine","Name":"Fexofenadine","Sub":false}]},{"Name":"Wikidata","Urls":[{"Link":"https://www.wikidata.org/wiki/Q415122","Name":"Fexofenadine","Sub":false}]},{"Name":"DrugBank","Urls":[{"Link":"https://go.drugbank.com/DB00950","Name":"Fexofenadine","Sub":false}]},{"Name":"PubChem","Urls":[{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/3348","Name":"Fexofenadine","Sub":false}]},{"Name":"Common Chemistry","Urls":[{"Link":"https://commonchemistry.cas.org/detail?cas_rn=83799-24-0","Name":"Fexofenadine","Sub":false}]},{"Name":"HMDB","Urls":[{"Link":"https://hmdb.ca/metabolites/HMDB0005030","Name":"Fexofenadine","Sub":false}]},{"Name":"KEGG","Urls":[{"Link":"https://www.kegg.jp/entry/C06999","Name":"Fexofenadine","Sub":false}]},{"Name":"UNII","Urls":[{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/E6582LOH6V","Name":"Fexofenadine","Sub":false}]},{"Name":"EPA DSSTox","Urls":[{"Link":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID00861411","Name":"Fexofenadine","Sub":false}]}],"Refs":["National Center for Biotechnology Information. PubChem Compound Summary for CID 3348, Fexofenadine. Accessed March 10, 2026. \u003ca href=https://pubchem.ncbi.nlm.nih.gov/compound/3348\u003ehttps://pubchem.ncbi.nlm.nih.gov/compound/3348\u003c/a\u003e","U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Fexofenadine. UNII: E6582LOH6V. Global Substance Registration System. Accessed March 10, 2026. \u003ca href=https://gsrs.ncats.nih.gov/ginas/app/beta/substances/E6582LOH6V\u003ehttps://gsrs.ncats.nih.gov/ginas/app/beta/substances/E6582LOH6V\u003c/a\u003e","Telfast 30mg Film-coated Tablets - Summary of Product Characteristics (SmPC). October 25, 2019. Accessed March 10, 2026. \u003ca href=https://www.medicines.org.uk/emc/product/5529/smpc\u003ehttps://www.medicines.org.uk/emc/product/5529/smpc\u003c/a\u003e","Almerg 180 mg Film-Coated Tablets - Summary of Product Characteristics (SmPC). Accessed March 10, 2026. \u003ca href=https://www.medicines.org.uk/emc/product/10147/smpc\u003ehttps://www.medicines.org.uk/emc/product/10147/smpc\u003c/a\u003e","Fexofenadine Hydrochloride 120 mg Film-Coated Tablets - Summary of Product Characteristics (SmPC). March 22, 2021. Accessed March 10, 2026. \u003ca href=https://www.medicines.org.uk/emc/product/10144/smpc\u003ehttps://www.medicines.org.uk/emc/product/10144/smpc\u003c/a\u003e"],"SMILES":"CC(C)(C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O)C(=O)O","SaltData":[{"AcidCount":1,"Amine":"Fexofenadine","AmineCount":1,"Formula":"Cl","Name":"hydrochloride","Structure":"\u003csvg xmlns=\"http://www.w3.org/2000/svg\" preserveAspectRatio=\"none\" style=\"display:block\" viewBox=\"0 0 179.429 197.11\"\u003e\u003crect width=\"100%\" height=\"100%\" fill=\"#fff\"/\u003e\u003cdesc\u003eGenerated by the Chemistry Development Kit (http://github.com/cdk)\u003c/desc\u003e\u003cg fill=\"#ff0d0d\" stroke=\"#000\" stroke-linecap=\"round\" stroke-linejoin=\"round\" stroke-width=\".7\"\u003e\u003cpath fill=\"#fff\" stroke=\"none\" d=\"M0 0h180v198H0z\"/\u003e\u003cg class=\"mol\"\u003e\u003cpath d=\"M33.522 196.2v-15.24M33.522 180.96l15.008 2.646M33.522 180.96l5.212-14.321\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m28.935 154.957 9.799 11.682M31.707 154.467l7.99 9.526\"/\u003e\u003cpath stroke=\"#ff0d0d\" d=\"m28.935 154.957 4.899 5.841\" class=\"hi\"/\u003e\u003c/g\u003e\u003cpath d=\"m28.935 154.957 5.208-14.332\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m49.151 137.976-15.008 2.649M48.188 140.622l-12.234 2.16\"/\u003e\u003c/g\u003e\u003cpath d=\"m49.151 137.976 9.8 11.683\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m53.742 163.99 5.209-14.331M51.932 161.834l4.246-11.686\"/\u003e\u003c/g\u003e\u003cpath d=\"m38.734 166.639 15.008-2.649M49.151 137.976l5.212-14.32M54.363 123.656l15.009-2.647M69.372 121.009l5.212-14.321M74.584 106.688l15.009-2.646M89.593 104.042l3.842-10.556M91.964 86.337 85 78.043M85 78.043l5.212-14.321M90.212 63.722l15.018-2.643M105.23 61.079l9.805 11.678M115.035 72.757l-5.212 14.321M98.125 89.137l11.698-2.059M105.23 61.079l5.212-14.321M110.442 46.758l15.009-2.646\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m130.661 29.781-5.21 14.331M132.472 31.938l-4.249 11.685\"/\u003e\u003c/g\u003e\u003cpath d=\"m130.661 29.781 15.009-2.646\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m155.468 38.819-9.798-11.684M152.695 39.308l-7.989-9.527\"/\u003e\u003c/g\u003e\u003cpath d=\"m155.468 38.819-5.211 14.33\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m135.249 55.796 15.008-2.647M136.212 53.15l12.235-2.157\"/\u003e\u003c/g\u003e\u003cpath d=\"m125.451 44.112 9.798 11.684M110.442 46.758v-15.24\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m97.234 23.898 13.208 7.62M99.673 22.49l10.769 6.213\"/\u003e\u003c/g\u003e\u003cpath d=\"M97.234 23.898V8.658\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m110.442 1.038-13.208 7.62M110.442 3.853l-10.769 6.213\"/\u003e\u003c/g\u003e\u003cpath d=\"m110.442 1.038 13.208 7.62\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"M123.65 23.898V8.658M121.212 22.49V10.066\"/\u003e\u003c/g\u003e\u003cpath d=\"m110.442 31.518 13.208-7.62M110.442 46.758l-11.37-2.005M54.363 123.656l-7.254-8.646M33.522 180.96l-13.198-7.62\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"M19.104 174.044v-12.023M21.543 174.044v-12.023\"/\u003e\u003cpath stroke=\"#ff0d0d\" d=\"M19.104 162.021v6.011M21.543 162.021v6.011\" class=\"hi\"/\u003e\u003c/g\u003e\u003cpath d=\"m20.324 173.34-9.92 5.727\" class=\"bond\"/\u003e\u003cpath fill=\"#3050f8\" stroke=\"none\" d=\"M96.746 92.171h-.72l-2.62-4.066h-.03l.03.595q.024.357.024.732v2.739h-.566v-4.9h.715l2.607 4.054h.03l-.018-.327-.024-.476q-.006-.262-.006-.483v-2.768h.578z\" class=\"atom\"/\u003e\u003cg stroke=\"none\" class=\"atom\"\u003e\u003cpath d=\"M97.693 44.109q0 .756-.256 1.327-.256.566-.756.881t-1.244.316q-.756 0-1.262-.316-.506-.315-.756-.887-.244-.571-.244-1.333 0-.75.244-1.31.25-.565.756-.881.506-.315 1.274-.315.732 0 1.232.315.5.31.756.875.256.566.256 1.328m-3.864 0q0 .922.387 1.458.393.53 1.221.53.839 0 1.22-.53.387-.536.387-1.458 0-.929-.387-1.453-.381-.524-1.208-.524-.834 0-1.227.524t-.393 1.453M92.613 46.561h-.619v-2.286h-2.512v2.286h-.614v-4.899h.614v2.072h2.512v-2.072h.619z\"/\u003e\u003c/g\u003e\u003cg stroke=\"none\" class=\"atom\"\u003e\u003cpath d=\"M46.827 111.978q0 .756-.256 1.328-.256.565-.756.881-.501.315-1.245.315-.756 0-1.262-.315-.506-.316-.756-.887-.244-.572-.244-1.334 0-.75.244-1.31.25-.565.756-.881.506-.315 1.274-.315.732 0 1.233.315.5.31.756.875.256.566.256 1.328m-3.864 0q0 .923.387 1.459.393.529 1.22.529.84 0 1.221-.529.387-.536.387-1.459 0-.929-.387-1.453-.381-.523-1.209-.523-.833 0-1.226.523-.393.524-.393 1.453M41.746 114.431h-.619v-2.286h-2.512v2.286h-.613v-4.9h.613v2.072h2.512v-2.072h.619z\"/\u003e\u003c/g\u003e\u003cpath stroke=\"none\" d=\"M22.583 158.097q0 .756-.256 1.328-.256.565-.756.881-.5.315-1.244.315-.756 0-1.262-.315-.506-.316-.757-.887-.244-.572-.244-1.334 0-.75.244-1.309.251-.566.757-.882.506-.315 1.274-.315.732 0 1.232.315.5.31.756.876.256.565.256 1.327m-3.864 0q0 .923.387 1.459.393.529 1.221.529.839 0 1.22-.529.387-.536.387-1.459 0-.929-.387-1.452-.381-.524-1.208-.524-.834 0-1.227.524-.393.523-.393 1.452\" class=\"atom\"/\u003e\u003cg stroke=\"none\" class=\"atom\"\u003e\u003cpath d=\"M9.385 180.957q0 .756-.256 1.328-.256.565-.756.881-.5.315-1.245.315-.756 0-1.262-.315-.506-.316-.756-.887-.244-.572-.244-1.334 0-.75.244-1.309.25-.566.756-.882.506-.315 1.274-.315.733 0 1.233.315.5.31.756.876.256.565.256 1.327m-3.864 0q0 .923.387 1.459.393.529 1.22.529.84 0 1.221-.529.387-.536.387-1.459 0-.929-.387-1.452-.381-.524-1.209-.524-.833 0-1.226.524-.393.523-.393 1.452M4.305 183.41h-.62v-2.286H1.173v2.286H.56v-4.9h.613v2.072h2.512v-2.072h.62z\"/\u003e\u003c/g\u003e\u003cpath stroke=\"#ff0d0d\" d=\"m28.935 154.957 2.604-7.166\" class=\"hi\"/\u003e\u003cpath stroke=\"#3050f8\" d=\"m93.435 93.486-1.921 5.278M91.964 86.337l-3.482-4.147M98.125 89.137l5.849-1.029\" class=\"hi\"/\u003e\u003cpath stroke=\"#ff0d0d\" d=\"m99.072 44.753 5.685 1.002M99.072 44.753l5.685 1.002M47.109 115.01l3.627 4.323M47.109 115.01l3.627 4.323M10.404 179.067l4.96-2.863M10.404 179.067l4.96-2.863\" class=\"hi\"/\u003e\u003c/g\u003e\u003cg class=\"mol\"\u003e\u003cg fill=\"#1ff01f\" stroke=\"none\" class=\"atom\"\u003e\u003cpath d=\"M176.113 96.704q-.786 0-1.239.529-.452.524-.452 1.447 0 .911.417 1.447.422.53 1.268.53.321 0 .607-.054.292-.06.565-.143v.536q-.273.101-.565.149-.292.053-.697.053-.744 0-1.25-.309-.5-.31-.75-.875-.25-.572-.25-1.34 0-.744.268-1.31.274-.565.804-.881.529-.321 1.28-.321.779 0 1.351.286l-.244.524q-.226-.102-.506-.185-.274-.083-.607-.083m2.756 4.423h-.601v-5.215h.601zM173.205 101.127h-.619v-2.286h-2.512v2.286h-.613v-4.9h.613v2.072h2.512v-2.072h.619z\"/\u003e\u003c/g\u003e\u003c/g\u003e\u003c/g\u003e\u003c/svg\u003e","Title":"Fexofenadine hydrochloride","UNII":"2S068B75ZU"}],"Salts":["hydrochloride"],"Scheduling":[{"gov":"Australia","ref":[],"schedule":"S2 substance"},{"gov":"Brazil","ref":[],"schedule":"OTC substance"},{"gov":"Canada","ref":[],"schedule":"OTC substance"},{"gov":"United Kingdom","ref":["3","4","5"],"schedule":"P substance"},{"gov":"United States","ref":[],"schedule":"OTC substance"}],"Solubility":"Slightly soluble","Stability/Shelf Life":"Commercially available fexofenadine hydrochloride capsules have an expiration date of 18 or 24 months after the date of manufacture when packaged in the manufacturer's unopened blister packages or high-density polyethylene bottles, respectively. Commercially available fexofenadine hydrochloride 30-mg conventional tablets have an expiration date of 18 months after the date of manufacture when packaged either in the manufacturer's unopened blister packages or high-density polyethylene bottles, whereas the commercially available fexofenadine hydrochloride 60-mg conventional tablets have an expiration date of 30 months after the date of manufacture when packaged either in the manufacturer's unopened blister packages or high-density polyethylene bottles. In addition, fexofenadine hydrochloride 180-mg conventional tablets have an expiration date of 18 or 30 months after the date of manufacture when packaged either in the manufacturer's unopened blister packages or high-density polyethylene bottles, respectively.","StereoisomerData":[],"StereoisomerType":"enantiomer","Stereoisomers":[],"Structure":"\u003csvg xmlns=\"http://www.w3.org/2000/svg\" preserveAspectRatio=\"none\" style=\"display:block\" viewBox=\"0 0 156.521 197.11\"\u003e\u003crect width=\"100%\" height=\"100%\" fill=\"#fff\"/\u003e\u003cdesc\u003eGenerated by the Chemistry Development Kit (http://github.com/cdk)\u003c/desc\u003e\u003cg fill=\"#ff0d0d\" stroke=\"#000\" stroke-linecap=\"round\" stroke-linejoin=\"round\" stroke-width=\".7\"\u003e\u003cpath fill=\"#fff\" stroke=\"none\" d=\"M0 0h157v198H0z\"/\u003e\u003cg class=\"mol\"\u003e\u003cpath d=\"M33.522 196.2v-15.24M33.522 180.96l15.008 2.646M33.522 180.96l5.212-14.321\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m28.935 154.957 9.799 11.682M31.707 154.467l7.99 9.526\"/\u003e\u003cpath stroke=\"#ff0d0d\" d=\"m28.935 154.957 4.899 5.841\" class=\"hi\"/\u003e\u003c/g\u003e\u003cpath d=\"m28.935 154.957 5.208-14.332\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m49.151 137.976-15.008 2.649M48.188 140.622l-12.234 2.16\"/\u003e\u003c/g\u003e\u003cpath d=\"m49.151 137.976 9.8 11.683\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m53.742 163.99 5.209-14.331M51.932 161.834l4.246-11.686\"/\u003e\u003c/g\u003e\u003cpath d=\"m38.734 166.639 15.008-2.649M49.151 137.976l5.212-14.32M54.363 123.656l15.009-2.647M69.372 121.009l5.212-14.321M74.584 106.688l15.009-2.646M89.593 104.042l3.842-10.556M91.964 86.337 85 78.043M85 78.043l5.212-14.321M90.212 63.722l15.018-2.643M105.23 61.079l9.805 11.678M115.035 72.757l-5.212 14.321M98.125 89.137l11.698-2.059M105.23 61.079l5.212-14.321M110.442 46.758l15.009-2.646\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m130.661 29.781-5.21 14.331M132.472 31.938l-4.249 11.685\"/\u003e\u003c/g\u003e\u003cpath d=\"m130.661 29.781 15.009-2.646\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m155.468 38.819-9.798-11.684M152.695 39.308l-7.989-9.527\"/\u003e\u003c/g\u003e\u003cpath d=\"m155.468 38.819-5.211 14.33\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m135.249 55.796 15.008-2.647M136.212 53.15l12.235-2.157\"/\u003e\u003c/g\u003e\u003cpath d=\"m125.451 44.112 9.798 11.684M110.442 46.758v-15.24\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m97.234 23.898 13.208 7.62M99.673 22.49l10.769 6.213\"/\u003e\u003c/g\u003e\u003cpath d=\"M97.234 23.898V8.658\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m110.442 1.038-13.208 7.62M110.442 3.853l-10.769 6.213\"/\u003e\u003c/g\u003e\u003cpath d=\"m110.442 1.038 13.208 7.62\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"M123.65 23.898V8.658M121.212 22.49V10.066\"/\u003e\u003c/g\u003e\u003cpath d=\"m110.442 31.518 13.208-7.62M110.442 46.758l-11.37-2.005M54.363 123.656l-7.254-8.646M33.522 180.96l-13.198-7.62\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"M19.104 174.044v-12.023M21.543 174.044v-12.023\"/\u003e\u003cpath stroke=\"#ff0d0d\" d=\"M19.104 162.021v6.011M21.543 162.021v6.011\" class=\"hi\"/\u003e\u003c/g\u003e\u003cpath d=\"m20.324 173.34-9.92 5.727\" class=\"bond\"/\u003e\u003cpath fill=\"#3050f8\" stroke=\"none\" d=\"M96.746 92.171h-.72l-2.62-4.066h-.03l.03.595q.024.357.024.732v2.739h-.566v-4.9h.715l2.607 4.054h.03l-.018-.327-.024-.476q-.006-.262-.006-.483v-2.768h.578z\" class=\"atom\"/\u003e\u003cg stroke=\"none\" class=\"atom\"\u003e\u003cpath d=\"M97.693 44.109q0 .756-.256 1.327-.256.566-.756.881t-1.244.316q-.756 0-1.262-.316-.506-.315-.756-.887-.244-.571-.244-1.333 0-.75.244-1.31.25-.565.756-.881.506-.315 1.274-.315.732 0 1.232.315.5.31.756.875.256.566.256 1.328m-3.864 0q0 .922.387 1.458.393.53 1.221.53.839 0 1.22-.53.387-.536.387-1.458 0-.929-.387-1.453-.381-.524-1.208-.524-.834 0-1.227.524t-.393 1.453M92.613 46.561h-.619v-2.286h-2.512v2.286h-.614v-4.899h.614v2.072h2.512v-2.072h.619z\"/\u003e\u003c/g\u003e\u003cg stroke=\"none\" class=\"atom\"\u003e\u003cpath d=\"M46.827 111.978q0 .756-.256 1.328-.256.565-.756.881-.501.315-1.245.315-.756 0-1.262-.315-.506-.316-.756-.887-.244-.572-.244-1.334 0-.75.244-1.31.25-.565.756-.881.506-.315 1.274-.315.732 0 1.233.315.5.31.756.875.256.566.256 1.328m-3.864 0q0 .923.387 1.459.393.529 1.22.529.84 0 1.221-.529.387-.536.387-1.459 0-.929-.387-1.453-.381-.523-1.209-.523-.833 0-1.226.523-.393.524-.393 1.453M41.746 114.431h-.619v-2.286h-2.512v2.286h-.613v-4.9h.613v2.072h2.512v-2.072h.619z\"/\u003e\u003c/g\u003e\u003cpath stroke=\"none\" d=\"M22.583 158.097q0 .756-.256 1.328-.256.565-.756.881-.5.315-1.244.315-.756 0-1.262-.315-.506-.316-.757-.887-.244-.572-.244-1.334 0-.75.244-1.309.251-.566.757-.882.506-.315 1.274-.315.732 0 1.232.315.5.31.756.876.256.565.256 1.327m-3.864 0q0 .923.387 1.459.393.529 1.221.529.839 0 1.22-.529.387-.536.387-1.459 0-.929-.387-1.452-.381-.524-1.208-.524-.834 0-1.227.524-.393.523-.393 1.452\" class=\"atom\"/\u003e\u003cg stroke=\"none\" class=\"atom\"\u003e\u003cpath d=\"M9.385 180.957q0 .756-.256 1.328-.256.565-.756.881-.5.315-1.245.315-.756 0-1.262-.315-.506-.316-.756-.887-.244-.572-.244-1.334 0-.75.244-1.309.25-.566.756-.882.506-.315 1.274-.315.733 0 1.233.315.5.31.756.876.256.565.256 1.327m-3.864 0q0 .923.387 1.459.393.529 1.22.529.84 0 1.221-.529.387-.536.387-1.459 0-.929-.387-1.452-.381-.524-1.209-.524-.833 0-1.226.524-.393.523-.393 1.452M4.305 183.41h-.62v-2.286H1.173v2.286H.56v-4.9h.613v2.072h2.512v-2.072h.62z\"/\u003e\u003c/g\u003e\u003cpath stroke=\"#ff0d0d\" d=\"m28.935 154.957 2.604-7.166\" class=\"hi\"/\u003e\u003cpath stroke=\"#3050f8\" d=\"m93.435 93.486-1.921 5.278M91.964 86.337l-3.482-4.147M98.125 89.137l5.849-1.029\" class=\"hi\"/\u003e\u003cpath stroke=\"#ff0d0d\" d=\"m99.072 44.753 5.685 1.002M99.072 44.753l5.685 1.002M47.109 115.01l3.627 4.323M47.109 115.01l3.627 4.323M10.404 179.067l4.96-2.863M10.404 179.067l4.96-2.863\" class=\"hi\"/\u003e\u003c/g\u003e\u003c/g\u003e\u003c/svg\u003e","Therapeutic Uses":"Histamine H1 antagonists","Title":"Fexofenadine","Treatment":"In the event of overdose, consider standard measures to remove any unabsorbed drug. Symptomatic and supportive treatment is recommended. (L1712)","UNII":"E6582LOH6V","Wikidata":"Q415122","Wikipedia":"Fexofenadine","XLogP":3}